Aurora Cannabis Inc. is open to considering a bid from a U.S. cannabis company aiming to acquire the Edmonton-based firm. The announcement of forming a special committee to review the unsolicited offer was made by Aurora following Curaleaf Holdings Inc.’s disclosure of its intention to acquire all shares of Aurora.
If successful, the acquisition would result in a merged cannabis entity operating in 17 countries across Europe, North America, and other global markets, according to Curaleaf. The company, based in Stamford, Conn., and listed on the Toronto Stock Exchange, stated that it decided to make its proposal public after unsuccessful private negotiations with Aurora’s leadership.
Curaleaf mentioned that despite sending formal letters of intent on June 23 and a follow-up on July 7 outlining the proposal details, Aurora’s board declined to engage in discussions. Boris Jordan, Curaleaf’s CEO, expressed disappointment over Aurora’s lack of meaningful engagement and emphasized the value and rationale behind the proposal.
Curaleaf’s proposal involves offering Aurora shareholders $4 US per share, along with an additional $0.75 US in cash for each Aurora share. Aurora acknowledged receiving the letters from Curaleaf but disputed Curaleaf’s claim that Aurora rejected the offer outright. The Canadian company clarified that discussions with Curaleaf’s CEO continued until late July.
Aurora plans to establish a special committee of independent directors to assess the bid’s merits and impact on stakeholders. However, the company cautioned that there is no certainty of reaching a deal, and it will maintain regular operations during the process.
Despite the interest shown by Curaleaf, analysts from TD Cowen believe that the current offer undervalues Aurora’s long-term potential. They highlighted Aurora’s strong market position in medical cannabis, quality product range, financial stability, and global regulatory expertise as factors that could generate significant value over time.
Curaleaf’s CEO emphasized the strategic benefits of the merger, citing the combined revenue of over $1.5 billion US in the past year and an expected $40 million US in annual cost savings. The proposed acquisition aims to leverage Curaleaf’s global distribution network with Aurora’s international medical cannabis business, cultivation capabilities, and manufacturing capacity.
In summary, the proposed merger is viewed as mutually beneficial, offering Aurora shareholders a chance to participate in a diversified global platform and tap into favorable regulatory trends in the U.S. cannabis market.